Daily close, T-120 (8/28/24) through T+5. Run-up high $30.19 on 10/16/24, low $24.8 on 11/22/24 (T-120 to T-1). FDA decision 2/12/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 29, 2025, 14 days before the decision date, at-the-money options priced a move of ±4.9% through Feb 14, 2025 (the first listed expiry after the decision; ATM implied volatility 29%). The stock closed -0.2% at the first close across the decision and +1.4% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-02-12
DrugADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3)
IndicationRelapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Was ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHE approved by the FDA?
Yes. The FDA approved the application for ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHE on February 12, 2025. The primary source is linked on this page.
What was ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHE under FDA review for?
The application covered Relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The FDA approved the application on February 12, 2025.
How did PFE stock react to the FDA decision?
On the decision day PFE moved -0.2%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.